BYSI BeyondSpring Inc Earnings per share for the last twelve months

BYSI (BeyondSpring, Inc.) - company brandmark

BeyondSpring Inc. (BYSI) is implementing predictive software and laboratory automation to discover molecules targeting lung cancer. Net income per share over the last 12 months (TTM) reflects profit dynamics, while -0.16 shows the current volume of this metric. The firm relies on partnerships with pharma behemoths regarding plinabulin and generates revenue from the procurement of neutropenia drugs by insurance funds.

BYSI (BeyondSpring Inc.) Net earnings per share for the last 12 months history from 07/04/2022 to 11/09/2026

BeyondSpring, Inc. - analytical breakdowns and key metrics (BYSI)

- current quotes and average value forecast:
Price Chart BeyondSpring Inc.|BYSI - Average Forecast Price
- market capitalization data:
Market Value BeyondSpring Inc.|BYSI - Business Value
- shareholders' equity book value data:
Book Value per Share BeyondSpring|BYSI - Company Net Assets|Market Value to Book Value Ratio beyondspringpharma.com|BYSI - Company Assets
- debt burden and liquidity indicators:
Debt to Equity BeyondSpring Inc.|BYSI - Long-Term Debt to Equity|Short-Term Debt to Equity BeyondSpring Pharma|BYSI - Company Cumulative Debt|Debts to Book Capitalization BeyondSpring Inc.|BYSI - Long-Term Indebtedness|Company Current Liabilities BeyondSpring|Quick Liquidity Indicator beyondspringpharma.com
- net income and valuation multiples indicators:
BYSI - Final Profit|Future Profit BeyondSpring Inc.|BYSI - Market Price to Net Income Ratio|Forward P/E Multiple BeyondSpring|BYSI - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple BeyondSpring Inc.|BYSI - Profit before interest, taxes and amortization|Earnings per share for the last twelve months BeyondSpring|BYSI - Earnings per share for the trailing year|Quarterly EPS earnings growth beyondspringpharma.com|BYSI - Earnings growth in current year|Net earnings per share growth forecast for next year BeyondSpring Inc.
Basic company analysis:BeyondSpring Inc. (BYSI)
Mass-produced product of BeyondSpring Pharma

BeyondSpring Inc. (BYSI) is developing a specialized oncology drug business utilizing a virtual management model. By analyzing net income per share, an investor can determine the actual earnings remaining per security after all expenses are deducted. This indicator isolates the overall financial result from the impact of the total shares outstanding. For a company utilizing outsourced testing, this metric confirms the efficiency of long-term vendor contracts. Steady growth in this metric indicates the fundamental stability of the operating model.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months hutch-med.com|Nuvation Bio (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (Monopar Pharma) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Inhibrx Corp (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics, Inc. HRTX|Nuvectis Pharma Inc. - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals, Inc.|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharma CTXR|Net earnings per share for the last 12 months CLRB (Cellectar)|BLRX (BioLineRx Corporation) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea Therapeutics Inc.)|Kazia - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (Silexion Therapeutics Corp)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Chimerix Inc (CMRX)|Earnings per share for the last twelve months Cyclacel Pharmaceuticals|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Therapeutics Inc (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech Corp) - Earnings per one share for the last 12 months